Results 121 to 130 of about 6,034 (197)

Start small: A model for tissue-wide planar cell polarity without morphogens. [PDF]

PLoS Comput Biol
Thayambath A, Belmonte JM.
europepmc   +1 more source

Event‐ and Time‐Based Prospective Memory and Time Perception in Autistic Adults With and Without Intellectual Disabilities

Autism Research, EarlyView.
ABSTRACT The aim of this study was to examine time perception (i.e., the sense of the duration, order and passage of time) and event‐ and time‐based prospective memory (PM; i.e., the ability to recall an intention to perform an action in the future) in adults across the wider autism spectrum including those with intellectual disabilities.
Daniela Nürnberg, Mareike Altgassen
wiley   +1 more source

Provider Attribution in Medicare: Challenges and Solutions. [PDF]

Health Serv Res
Carlin CS, Feldman R, Jung J.
europepmc   +1 more source

Associations Between Comorbidities, Developmental Status, and Disease Severity in Children With Autism Spectrum Disorder: A Multicenter Cross‐Sectional Study in China

Autism Research, EarlyView.
ABSTRACT Children with autism spectrum disorder (ASD) frequently present with co‐occurring conditions that can influence autism symptom severity and complicate clinical management. However, studies with clinician‐confirmed diagnoses in non‐Western populations remain limited.
Dizhou Pang, Guiqin Duan, Qing Shang, Huichun Zhang, Binbin Wang, Huaili Ding, Huihui Kang, Yue Zhao, Yuxia Lu, Gai Tian, Li Zhang, Wu Jiang, Ganyu Wang, Cailing Liang, Lingling Zhang, Bingbing Li, Zhenghua Li, Chunlan Song, Yanyan Yang, Yazhe Wang, Kaichen Yue, Yongbin Lang, Jiatian Liu, Xiaoli Zhang, Yiran Xu, Changlian Zhu   +25 more
wiley   +1 more source

Comparative analysis of tissue-specific anticancer peptide prediction models: ACP-Boost framework. [PDF]

Front Mol Biosci
Kang R, Yuan W, Tang M, Zhou H.
europepmc   +1 more source

5‐Methylcytosine Analysis of miRNAs in Minimal Change Disease

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Minimal change disease (MCD) is a glomerular disorder, which is the most common cause of nephrotic syndrome in children. Additionally, the prevalence of MCD in adults has been increasing in recent years. During protein synthesis, noncoding RNAs can be regulated through a variety of modifications, which helps preserve biological diversity and ...
Huiyi Zeng, Dandan Li, Yunyi Li, Chen Yun, Xinzhou Zhang, Wenyu Gong, Mengyun Xiao, Haitao Li, Zhipeng Zeng, Ruqi Tan, Yishen Yang, Shaodong Luan, Yong Dai, Lianghong Yin, Donge Tang   +14 more
wiley   +1 more source

An innovative health systems approach to support early detection of cognitive impairment in primary care - the brain health navigator. [PDF]

BMC Prim Care
Brosch JR, Summanwar D, Fowler NR, Hammers DB, Perkins AJ, Higbie A, Swartzell K, Willis DR.   +7 more
europepmc   +1 more source

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

British Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić, Elvira Meni Maria Gkrinia, Patrick Eustaquio, Andrea Katrin Faour, Dinko Vitezić   +4 more
wiley   +1 more source

Additional Investigations and Referrals by Primary Care Physicians in Uncertain Clinical Situations: Cross-Sectional Study Using Virtual Patient-Based Scenarios. [PDF]

JMIR Form Res
Lorenzo M, Pelaccia T, Triby E, Can Y, Krider R, Maisonneuve H, Fernandez N.   +6 more
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source